A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

July 26, 2023

Study Completion Date

July 26, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

Envofolimab

300mg,Q3W (arm A,B and C)or 200mg, Q2W(arm D)

DRUG

BD0801

2mg/kg,Q3W(armA, B and C) or 2mg/kg,Q2W

DRUG

Docetaxel

75mg/m2,Q3W

DRUG

Irinotecan

180 mg/m2,Q2W

DRUG

Leucovorin calcium

400mg/m2,Q2W

DRUG

5-Fluorouridine

2400 mg/m2,Q2W

Trial Locations (24)

Unknown

Beijing Cancer Hospital, Beijing

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Jilin Cancer Hospital, Changchun

Hunan Cancer Hospital, Changsha

Sichuan Cancer Hospital, Chengdu

Dezhou People'S Hospital, Dezhou

First Affiliated Hospital of Gannan Medical Universit, Ganzhou

Nanfang Hospital of Southern Medical University, Guangzhou

Sun Yat-sen University affiliated with the Sixth Hospital, Guangzhou

Sun Yat-sen University Cancer Center, Guangzhou

Shaw Hospital Affiliated to Medical College of Zhejiang Universit, Hangzhou

Zhejiang Provincial People'S Hospital, Hangzhou

Harbin Medical University Cancer Hospital, Harbin

Anhui Chest Hospital, Hefei

Anhui Provincial Cancer Hospital, Hefei

The First Affliated Hospital Of Anhui Medical University, Hefei

Shandong Cancer Hospital, Jinan

Mianyang Central Hospital, Mianyang

Liaoning Cancer Hospital, Shenyang

The Fourth Hospital of Hebei Medical University, Shijia Zhuang

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Yantai Yuhuagnding Hospital, Yantai

Henan Cancer Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY